+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome



Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome



Cochrane Database of Systematic Reviews 2000(2): Cd001302



Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition that occurs after the administration of human menopausal gonadotrophin (hMG) with or without gonadotrophin releasing hormone (GnRH) agonists. OHSS is a threat to every woman undergoing ovulation induction and is potentially lethal in its severest form. Severe OHSS is characterised by growth of multiple large follicles with massive extravascular protein rich fluid shift. This may lead to hypovolaemia, haemoconcentration, oliguria, and electrolyte disturbance. Human albumin solutions are now used in the management of shock and other conditions in which restoration of blood volume is urgent, the acute management of burns, and clinical situations associated with hypoproteinaemia. Recently, a number of clinical trials with conflicting results have been reported in which albumin has been tested as a possible way for preventing the severe form of OHSS. To review the effectiveness of human albumin administration in prevention of severe ovarian hyperstimulation syndrome. The Menstrual Disorders and Subfertility Group literature search strategy was used to identify randomised trials that had compared the use of human albumin with placebo or no treatment in the prevention of severe ovarian hyperstimulation syndrome. A diverse search strategy was employed, including handsearching of core journals from 1966 to the present, searching bibliographies of relevant trials, MEDLINE, EMBASE, PsychLIT and CINAHL databases, the MDSG specialised register, abstracts from North American and European meetings and contact with authors of relevant papers. Trials were included if they compared the effect of human albumin with placebo or no treatment on relevant outcomes. Only randomised controlled studies were included in this review. Trials under consideration were evaluated for methodological quality and appropriateness for inclusion without consideration of their results. Relevant data were extracted independently by two reviewers using the standardized data extraction sheet. Validity was assessed in terms of method of randomization, completeness of follow-up, presence or absence of crossover and co-intervention. 2x2 tables were generated for all relevant outcomes. Odds ratios were calculated using the Peto modified Mantel-Haenszel technique. Meta-analysis of the three included trials demonstrated significant reduction in severe ovarian hyperstimulation syndrome on administration of human albumin (common odds ratio 0.1, 95% confidence interval 0.03 to 0.39). There was no evidence of an increase in the pregnancy rate (common odds ratio 1.69, 95% confidence interval 0.7 to 4.07). This review shows a clear benefit from administration of intra-venous albumin at the time of oocyte retrieval in prevention of severe OHSS in high-risk cases. However, the results of this review can not be regarded as conclusive as they are based on only three small trials. Further trials are urgently needed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046448676

Download citation: RISBibTeXText

PMID: 10796765

DOI: 10.1002/14651858.cd001302


Related references

Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Human Reproduction 17(12): 3027-3032, 2002

Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2011(2): Cd001302, 2011

Bilateral internal jugular venous thrombosis complicating severe ovarian hyperstimulation syndrome after prophylactic albumin administration. Fertility & Sterility. 68(1): 174-176, 1997

Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 10(10): 2750-2752, 1995

Does intravenous albumin prevent severe ovarian hyperstimulation syndrome?. Fertility and Sterility 71(2): 387-388, 1999

Severe ovarian hyperstimulation syndrome: Is it really preventable by prophylactic intravenous albumin?. Fertility & Sterility 68(5): 851-854, 1997

Prophylactic intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 11(2): 460-461, 1996

The role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 14(ABSTR BOOK 1): 167, 1999

Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertility & Sterility. 68(2): 287-291, 1997

Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction 13(12): 3306-3309, 1998

The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Human Reproduction 8(7): 1015-1020, 1993

does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?. Fertility and Sterility 66(4): 654-656, 1996

Hydroxyethylstarch versus human albumin for treatment of severe ovarian hyperstimulation syndrome. Human Reproduction 16(Abstract Book 1): 121, 2001

A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertility and Sterility 64(4): 860-862, 1995

Severe ovarian hyperstimulation syndrome and deep venous thrombosis. Lancet 2(8670): 1043, 1989